颅内动脉瘤最主要危害是破裂出血，近期研究发现其破裂与动脉瘤血流动力学及瘤壁药代动力学改变直接相关。本课题拟采用invivo公司32通道线圈、自主研发的4倍SENSE图像采集加速技术，通过核磁共振三维动态相位对比成像（4D Flow MRI）直接获得动脉瘤腔真实的血流速度和流量信息, 同时联合基于黑血成像技术与新的药代动力学方法3.0T 高分辨率动态增强磁共振（DCE-MRI）检测动脉瘤瘤壁的药代动力学参数，分析临床破裂与未破裂动脉瘤血流动力学和药代动力学特征差异，随后对动脉瘤手术标本的瘤壁组织进行病理结构及分子病理水平的检测，进一步验证动脉瘤血流动力学及药代动力学变化与其破裂的相关性；并对未治疗的动脉瘤患者进行破裂危险度的前瞻性追踪随访进而修正动脉瘤血流动力学及药代动力学相关参数，用来个体化评估动脉瘤瘤壁稳定性与破裂危险度，为动脉瘤破裂风险的精准预警及治疗决策提供参考依据。

The main hazard of intracranial aneurysm is rupture, and recent study found that rupture of aneurysm is directly related to change of hemodynamic in the aneurysm cavity and the change of the pharmacokinetics of aneurysm wall. The study intends to use this project invivo 32-channel coil, self-developed four times SENSE accelerated image capture technology and three-dimensional visualization technology to obtain the true flow velocity and flow of information aneurysm cavity derictly through three-dimensional dynamic phase contrast imaging MRI (4D Flow MRI) technology. On this basis, using enhanced MRI (DCE-MRI) based on dynamic black blood imaging technology and new pharmacokinetic methods to detect the pharmacokinetics parameters in aneurysm wall. Thus we can analyze the differences of hemodynamic and pharmacokinetic changes between patients with ruptured and unruptured intracranial aneurysms. At the same time, the histopathological and molecular pathology examination of intracranial aneurysm specimens is carried out to analyze the association between hemodynamic，pharmacokinetic changes and aneurismal rupture. Finally, we will revise hemodynamic and pharmacokinetic parameters by clinical follow-up of the aneurysm patients who do not undergo endovascular or surgical treatment, to evaluate the stability of the aneurysm wall and risk of aneurysm rupture, thus provide references for clinical evaluation of intracranial aneurysm.